Divis Laboratories
BSE 532488 · ISIN INE361B01024
3 stories, newest first.
- Viewer asked which is better between Divi's Labs and Syngene in CDMO space; analyst preferred Divi's
- Board meeting on November 7 to approve unaudited results for Q2 and H1 of FY 2026-27
- Divi's Lab in focus after Eli Lilly's anti-diabetes drug, for which Divi's manufactures an intermediate, received positive response in Europe
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.